From Powerbase
Jump to: navigation, search

In 2000, Warner-Lambert merged with Pfizer[1]

Warner-Lambert was listed as a client of business intelligence firm Business Insights[2]


In 2004, Warner Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities in connection with its illegal and fraudulent promotion of unapproved uses for its drug Neurontin[3]. The U.S. department of Justice report that 'Warner-Lambert's strategic marketing plans, as well as other evidence, show that Neurontin was aggressively marketed to treat a wide array of ailments for which the drug was not approved'. They go on to add that Warner-Lambert promoted Neurontin even when scientific studies had shown that it was not effective and for uses that had been specifically rejected by the FDA.